New hope for Hard-to-Treat lung condition: satralizumab trial targets inflammation

NCT ID NCT05679570

Completed Disease control Sponsor: International University of Health and Welfare Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jul 16, 2026 · Updated 2 times

Summary

This Phase 2 trial tests whether satralizumab, an antibody that blocks IL-6 (a protein involved in inflammation), can improve blood flow in the lungs of people with pulmonary arterial hypertension (PAH). The study includes 20 adults in Japan who have high IL-6 levels and haven't responded well to standard treatments. Participants receive satralizumab injections every few weeks, and researchers measure changes in lung blood vessel resistance and walking distance after 24 weeks.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Satralizumab (an anti-IL-6 receptor antibody)
What this could lead to: If successful, this could provide a new treatment option for people with pulmonary arterial hypertension who have high IL-6 levels and don't respond well to existing drugs.
What could go wrong: This is a small, early-stage Phase 2 trial with only 20 participants in Japan. It may not show enough benefit or could have side effects, and results may not apply to all PAH patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PULMONARY ARTERIAL HYPERTENSION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

pulmonary arterial hypertension

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PULMONARY ARTERIAL HYPERTENSION

Contacts and locations

Locations

Chiba University Hospital

Chiba, 260-8677, Japan
Hokkaido University Hospital

Sapporo, 060-8648, Japan
International University of Health and Welfare Mita Hospital

Tokyo, 108-8329, Japan
Kagoshima University Hospital

Kagoshima, Kagoshima-ken, 890-8520, Japan
Kobe University Hospital

Kobe, 650-0017, Japan
Kurume University Hospital

Kurume, 830-0011, Japan
Kyorin University Hospital

Mitaka, 181-8611, Japan
Kyushu University Hospital

Fukuoka, 812-8582, Japan
Nagoya University Hospital

Nagoya, 466-8560, Japan

More trials for these conditions

Other studies related to the condition(s) this trial covers.